Related Experiment Videos
Feverfew--an antithrombotic drug?
W Loesche1, A V Mazurov, T A Voyno-Yasenetskaya
1Institute of Pathological Biochemistry, Medical Academy of Erfurt, GDR.
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1988
Summary
Feverfew extract (FE) was found to inhibit platelet deposition and aggregation on collagen surfaces. This plant extract also protected endothelial cell (EC) layers, suggesting potential antithrombotic benefits.
Area of Science:
- Pharmacology
- Biochemistry
- Cardiovascular Research
Background:
- Platelet interaction with collagen is crucial in thrombosis.
- Endothelial cell (EC) integrity is vital for vascular health.
- Feverfew is traditionally used for various ailments, but its vascular effects are less understood.
Purpose of the Study:
- To investigate the effects of feverfew extract (FE) on platelet-collagen interactions.
- To assess FE's impact on endothelial cell (EC) monolayer integrity.
- To explore the potential antithrombotic properties of feverfew.
Main Methods:
- Studied platelet deposition and aggregation on type III and IV collagen (CIII, CIV) surfaces using [51Cr]-labelled platelets.
- Assessed FE's effect on platelet-rich plasma and washed platelets.
- Examined EC monolayer integrity in perfused rabbit aorta segments exposed to FE.
Main Results:
- FE dose-dependently inhibited platelet deposition on both CIII and CIV.
- Similar FE concentrations inhibited platelet aggregate formation on CIII and spreading on CIV.
- FE protected the EC monolayer from injury in perfused aorta segments.
Conclusions:
- Feverfew extract demonstrates significant antithrombotic potential by inhibiting platelet-collagen interactions.
- FE safeguards endothelial cell integrity, suggesting a protective role in vascular function.
- These findings support further research into feverfew's therapeutic applications for thrombotic disorders.